Literature DB >> 8000507

Correlation between serum levels of alanine aminotransferase and ferritin in male blood donors with antibody to hepatitis C virus.

T Takikawa1, H Hayashi, N Nishimura, M Yano, T Isomura, N Sakamoto.   

Abstract

Chronic hepatitis C has been demonstrated to be associated with hepatic iron overload, and the hypothesis that the disease activity of hepatitis C is associated with iron cytotoxicity was tested in male volunteer blood donors. Sera with either antibody to hepatitis C virus or hepatitis B surface antigen were selected for determination of ferritin concentration and alanine aminotransferase activity. A correlation between serum ferritin concentration (Y; microgram/l) and alanine aminotransferase activity (X; IU/l) was found in donors with antibody to hepatitis C (log Y = 0.65 x log X + 0.98, r = 0.53, and P < 0.01). The correlation was lower in donors with hepatitis B surface antigen (r = 0.37; P < 0.01). Hepatitis C virus infection probably induces time-dependent iron accumulation associated with the progression of disease activity, while hepatitis B virus infection results in a variety of iron loads with different clinical features. The high disease activity related to hyperferritinemia suggests the presence of iron-induced liver damage in donors with hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8000507     DOI: 10.1007/BF02365441

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  5 in total

1.  Measurements of iron status in patients with chronic hepatitis.

Authors:  A M Di Bisceglie; C A Axiotis; J H Hoofnagle; B R Bacon
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

2.  Serum ferritin in Nigerian patients with amoebic liver abscess and other tropical infections with liver involvement.

Authors:  D M Bolarin
Journal:  Acta Trop       Date:  1983-06       Impact factor: 3.112

3.  Serum ferritin as a predictor of host response to hepatitis B virus infection.

Authors:  E D Lustbader; H W Hann; B S Blumberg
Journal:  Science       Date:  1983-04-22       Impact factor: 47.728

4.  Serum ferritin in patients with iron overload and with acute and chronic liver diseases.

Authors:  J Prieto; M Barry; S Sherlock
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

5.  Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection.

Authors:  A Piperno; S Fargion; R D'Alba; L Roffi; A L Fracanzani; L Vecchi; M Failla; G Fiorelli
Journal:  J Hepatol       Date:  1992-11       Impact factor: 25.083

  5 in total
  4 in total

1.  Novel assessment of hepatic iron distribution by synchrotron radiation X-ray fluorescence microscopy.

Authors:  Hisoka Kinoshita; Yuichi Hori; Takumi Fukumoto; Takuji Ohigashi; Kunio Shinohara; Yoshitake Hayashi; Yonson Ku
Journal:  Med Mol Morphol       Date:  2010-03-26       Impact factor: 2.309

2.  Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C.

Authors:  Tsung-Jung Lin; Li-Ying Liao; Shyr-Yi Lin; Chih-Lin Lin; Ting-An Chang
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

3.  Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection.

Authors:  Yusuke Kawamura; Norio Akuta; Hitomi Sezaki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2005-09       Impact factor: 7.527

4.  Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.

Authors:  Nobuyuki Matsumoto; Hiroki Ikeda; Ryuta Shigefuku; Nobuhiro Hattori; Tsunamasa Watanabe; Kotaro Matsunaga; Tetsuya Hiraishi; Tomohiro Tamura; Yohei Noguchi; Yasunobu Fukuda; Toshiya Ishii; Chiaki Okuse; Akira Sato; Michihiro Suzuki; Fumio Itoh
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.